Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different
ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and
help kill them or carry cancer-killing substances to them. Bortezomib may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood
flow to the tumor. Drugs used in chemotherapy, such as doxorubicin, dexamethasone, and
chlorambucil, work in different ways to stop the growth of cancer cells, either by killing
the cells or by stopping them from dividing. Giving combination chemotherapy together with
rituximab and bortezomib may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving rituximab together with bortezomib,
doxorubicin, dexamethasone, and chlorambucil works as first-line therapy in treating older
patients with stage II, stage III, or stage IV mantle cell lymphoma.